DeAngelo V, Gehan A, Paliwal S, Ho K, Hilliard J, Chiang C
Brain Commun. 2024; 6(5):fcae246.
PMID: 39464215
PMC: 11503953.
DOI: 10.1093/braincomms/fcae246.
Mirabella G, Pilotto A, Rizzardi A, Montalti M, Olivola E, Zatti C
Brain Commun. 2024; 6(1):fcad350.
PMID: 38162902
PMC: 10757450.
DOI: 10.1093/braincomms/fcad350.
Georgiev D, Torkmani A, Song R, Limousin P, Jahanshahi M
Mov Disord Clin Pract. 2023; 10(10):1485-1495.
PMID: 37868920
PMC: 10585975.
DOI: 10.1002/mdc3.13863.
Beauchamp L, Dore V, Villemagne V, Xu S, Finkelstein D, Barnham K
Neurology. 2023; 101(22):e2314-e2324.
PMID: 37816639
PMC: 10727223.
DOI: 10.1212/WNL.0000000000207748.
Mann L, Servant M, Hay K, Song A, Trujillo P, Yan B
J Cogn Neurosci. 2023; 35(11):1806-1822.
PMID: 37677065
PMC: 10594953.
DOI: 10.1162/jocn_a_02048.
F-DOPA PET imaging identifies a dopaminergic deficit in a rat model with a G51D α-synuclein mutation.
Morley V, Dolt K, Alcaide-Corral C, Walton T, Lucatelli C, Mashimo T
Front Neurosci. 2023; 17:1095761.
PMID: 37292159
PMC: 10244711.
DOI: 10.3389/fnins.2023.1095761.
Relevance of F-DOPA visual and semi-quantitative PET metrics for the diagnostic of Parkinson disease in clinical practice: a machine learning-based inference study.
Iep A, Chawki M, Goldfarb L, Nguyen L, Brulon V, Comtat C
EJNMMI Res. 2023; 13(1):13.
PMID: 36780091
PMC: 9925664.
DOI: 10.1186/s13550-023-00962-x.
Cortical oscillatory dysfunction in Parkinson disease during movement activation and inhibition.
Disbrow E, Glassy N, Dressler E, Russo K, Franz E, Turner R
PLoS One. 2022; 17(3):e0257711.
PMID: 35245294
PMC: 8896690.
DOI: 10.1371/journal.pone.0257711.
Parkinson's disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI.
Depierreux F, Parmentier E, Mackels L, Baquero K, Degueldre C, Balteau E
NPJ Parkinsons Dis. 2021; 7(1):57.
PMID: 34238927
PMC: 8266835.
DOI: 10.1038/s41531-021-00199-2.
Pharmacokinetic Modeling of F-FDOPA PET in the Human Brain for Early Parkinson's Disease.
Buratachwatanasiri W, Chantadisai M, Onwanna J, Chongpison Y, Rakvongthai Y, Khamwan K
Mol Imaging Radionucl Ther. 2021; 30(2):69-78.
PMID: 34082499
PMC: 8185476.
DOI: 10.4274/mirt.galenos.2021.08831.
Imaging the Functional Neuroanatomy of Parkinson's Disease: Clinical Applications and Future Directions.
Lauretani F, Longobucco Y, Ravazzoni G, Gallini E, Salvi M, Maggio M
Int J Environ Res Public Health. 2021; 18(5).
PMID: 33670940
PMC: 7967767.
DOI: 10.3390/ijerph18052356.
Imaging Familial and Sporadic Neurodegenerative Disorders Associated with Parkinsonism.
Brooks D
Neurotherapeutics. 2021; 18(2):753-771.
PMID: 33432494
PMC: 8423977.
DOI: 10.1007/s13311-020-00994-4.
Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson's disease.
Fricova D, Korchak J, Zubair A
NPJ Regen Med. 2020; 5(1):20.
PMID: 33298940
PMC: 7641157.
DOI: 10.1038/s41536-020-00106-y.
Circulating Metabolites as Potential Biomarkers for Neurological Disorders-Metabolites in Neurological Disorders.
Donatti A, Canto A, Godoi A, da Rosa D, Lopes-Cendes I
Metabolites. 2020; 10(10).
PMID: 33003305
PMC: 7601919.
DOI: 10.3390/metabo10100389.
Association Between a Variable Number Tandem Repeat Polymorphism Within the DAT1 Gene and the Mesolimbic Pathway in Parkinson's Disease.
Du Plessis S, Bekker M, Buckle C, Vink M, Seedat S, Bardien S
Front Neurol. 2020; 11:982.
PMID: 32982958
PMC: 7493621.
DOI: 10.3389/fneur.2020.00982.
Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization.
Trifonova O, Maslov D, Balashova E, Urazgildeeva G, Abaimov D, Fedotova E
Diagnostics (Basel). 2020; 10(5).
PMID: 32466249
PMC: 7277996.
DOI: 10.3390/diagnostics10050339.
Impaired Fine Motor Function of the Asymptomatic Hand in Unilateral Parkinson's Disease.
Dan X, Liu J, Doyon J, Zhou Y, Ma J, Chan P
Front Aging Neurosci. 2019; 11:266.
PMID: 31636557
PMC: 6787142.
DOI: 10.3389/fnagi.2019.00266.
Acrolein-mediated alpha-synuclein pathology involvement in the early post-injury pathogenesis of mild blast-induced Parkinsonian neurodegeneration.
Acosta G, Race N, Herr S, Fernandez J, Tang J, Rogers E
Mol Cell Neurosci. 2019; 98:140-154.
PMID: 31201929
PMC: 6690849.
DOI: 10.1016/j.mcn.2019.06.004.
Reduced habit-driven errors in Parkinson's Disease.
Bannard C, Leriche M, Bandmann O, Brown C, Ferracane E, Sanchez-Ferro A
Sci Rep. 2019; 9(1):3423.
PMID: 30833640
PMC: 6399280.
DOI: 10.1038/s41598-019-39294-z.
Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.
Geibl F, Henrich M, Oertel W
J Neural Transm (Vienna). 2019; 126(4):377-396.
PMID: 30643975
DOI: 10.1007/s00702-019-01970-9.